Search research articles
Contact Us
Filters
Showing results (31-40 of 47) with videos related to
Page
of 5
Sort By:
Human Vaccines & Immunotherapeutics
|
March 20, 2018
Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine
Karl-Ulrich Petry, Kaatje Bollaerts, Paolo Bonanni, et al.
The Lancet. Oncology
|
November 12, 2017
Incomplete excision of cervical precancer as a predictor of treatment failure: a systematic review and meta-analysis
Marc Arbyn, Charles W E Redman, Freija Verdoodt, et al.
BMJ (Clinical Research Ed.)
|
October 15, 2008
Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study
Joakim Dillner, Matejka Rebolj, Philippe Birembaut, et al.
Journal of Clinical Laboratory Analysis
|
February 14, 2019
Intra- and inter-laboratory agreement of the FAM19A4/mir124-2 methylation test: Results from an international study
Arno Floore, Albertus Hesselink, Anja Oštrbenk, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 29, 2011
Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO
Philipp Harter, Jalid Sehouli, Alexander Reuss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 15, 2009
Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer
Michael Untch, Volker Möbus, Walther Kuhn, et al.
Nature Reviews. Clinical Oncology
|
September 2, 2015
HPV-FASTER: broadening the scope for prevention of HPV-related cancer
F Xavier Bosch, Claudia Robles, Mireia Díaz, et al.
International Journal of Cancer
|
September 30, 2020
Methylation markers FAM19A4 and miR124-2 as triage strategy for primary human papillomavirus screen positive women: A large European multicenter study
Jesper Bonde, Arno Floore, Ditte Ejegod, et al.
The Journal of Infectious Diseases
|
June 8, 2017
Sustained Immunogenicity of 2-dose Human Papillomavirus 16/18 AS04-adjuvanted Vaccine Schedules in Girls Aged 9-14 Years: A Randomized Trial
Li-Min Huang, Thanyawee Puthanakit, Chiu Cheng-Hsun, et al.
American Journal of Obstetrics and Gynecology
|
January 16, 2021
p53 and p16 expression profiles in vulvar cancer: a translational analysis by the Arbeitsgemeinschaft Gynäkologische Onkologie Chemo and Radiotherapy in Epithelial Vulvar Cancer study group
Linn Woelber, Katharina Prieske, Christine Eulenburg, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 47) with videos related to
Sort By:
Page
of 5
Human Vaccines & Immunotherapeutics
|
March 20, 2018
Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine
Karl-Ulrich Petry, Kaatje Bollaerts, Paolo Bonanni, et al.
The Lancet. Oncology
|
November 12, 2017
Incomplete excision of cervical precancer as a predictor of treatment failure: a systematic review and meta-analysis
Marc Arbyn, Charles W E Redman, Freija Verdoodt, et al.
BMJ (Clinical Research Ed.)
|
October 15, 2008
Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study
Joakim Dillner, Matejka Rebolj, Philippe Birembaut, et al.
Journal of Clinical Laboratory Analysis
|
February 14, 2019
Intra- and inter-laboratory agreement of the FAM19A4/mir124-2 methylation test: Results from an international study
Arno Floore, Albertus Hesselink, Anja Oštrbenk, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 29, 2011
Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO
Philipp Harter, Jalid Sehouli, Alexander Reuss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 15, 2009
Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer
Michael Untch, Volker Möbus, Walther Kuhn, et al.
Nature Reviews. Clinical Oncology
|
September 2, 2015
HPV-FASTER: broadening the scope for prevention of HPV-related cancer
F Xavier Bosch, Claudia Robles, Mireia Díaz, et al.
International Journal of Cancer
|
September 30, 2020
Methylation markers FAM19A4 and miR124-2 as triage strategy for primary human papillomavirus screen positive women: A large European multicenter study
Jesper Bonde, Arno Floore, Ditte Ejegod, et al.
The Journal of Infectious Diseases
|
June 8, 2017
Sustained Immunogenicity of 2-dose Human Papillomavirus 16/18 AS04-adjuvanted Vaccine Schedules in Girls Aged 9-14 Years: A Randomized Trial
Li-Min Huang, Thanyawee Puthanakit, Chiu Cheng-Hsun, et al.
American Journal of Obstetrics and Gynecology
|
January 16, 2021
p53 and p16 expression profiles in vulvar cancer: a translational analysis by the Arbeitsgemeinschaft Gynäkologische Onkologie Chemo and Radiotherapy in Epithelial Vulvar Cancer study group
Linn Woelber, Katharina Prieske, Christine Eulenburg, et al.
Page
of 5